Vanda Pharmaceuticals (VNDA) Stock Price, News & Analysis

Company Overview

Vanda Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development and commercialization of therapies for central nervous system (CNS) disorders. The company’s research efforts are concentrated on conditions related to sleep and neurological diseases, with several late-stage and approved products addressing unmet medical needs. Vanda’s portfolio and pipeline reflect its commitment to innovative drug development in areas where treatment options are limited and patient populations are underserved.

Among Vanda’s marketed products is Hetlioz (tasimelteon), a melatonin receptor agonist approved for the treatment of non-24-hour sleep-wake disorder in totally blind individuals. The company has also developed Fanapt (iloperidone), an atypical antipsychotic for schizophrenia, and Trudhesa (dihydroergotamine mesylate nasal spray) to address acute migraine attacks in adults. Vanda continues to advance its pipeline with investigational candidates targeting hepatic encephalopathy, dopamine-regulated disorders and other therapeutic areas within the CNS space.

Founded in 2003 and headquartered in Washington, D.C., Vanda Pharmaceuticals operates a global research and development infrastructure, with facilities in North America and Europe. The company leverages strategic partnerships and collaborations to enhance its clinical programs and streamline regulatory pathways. Vanda’s team engages in ongoing dialogue with regulatory agencies to support its late-stage trials and potential label expansions for existing products.

Under the leadership of President and Chief Executive Officer Mihael H. Polymeropoulos, Vanda maintains a scientific-driven approach, supported by an executive team with deep experience in neuroscience and drug commercialization. The company’s strategic priorities include advancing late-stage assets through pivotal studies, exploring new indications, and expanding its commercial footprint to better serve patients with CNS disorders worldwide.

Key Stats

• Today's Range: $4.86 to $5.04
• 50-Day Range: $3.92 to $4.99
• 52-Week Range: $3.81 to $6.37
• Volume: 293,730 shs
• Average Volume: 602,398 shs
• Market Capitalization: $294.30 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $16.50
• Consensus Rating: Strong Buy

Vanda Pharmaceuticals Stock Analysis - MarketRank™

Vanda Pharmaceuticals scored higher than 88% of companies evaluated by MarketBeat, and ranked 120th out of 922 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.8 / 5
• Analyst Rating: Strong Buy

Consensus Rating

Vanda Pharmaceuticals has received a consensus rating of Strong Buy. The company's average rating score is 3.50, and is based on 1 buy rating, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Vanda Pharmaceuticals has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Vanda Pharmaceuticals are expected to grow in the coming year, from ($1.12) to ($0.27) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Vanda Pharmaceuticals is -6.66, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Vanda Pharmaceuticals is -6.66, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Vanda Pharmaceuticals has a P/B Ratio of 0.54. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

8.62% of the float of Vanda Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Vanda Pharmaceuticals has a short interest ratio ("days to cover") of 8.7.

Change versus previous month

Short interest in Vanda Pharmaceuticals has recently decreased by 0.63%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Vanda Pharmaceuticals does not currently pay a dividend.

Dividend Growth

Vanda Pharmaceuticals does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.2 / 5
• Environmental Score: -1.77

Percentage of Shares Shorted

8.62% of the float of Vanda Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Vanda Pharmaceuticals has a short interest ratio ("days to cover") of 8.7.

Change versus previous month

Short interest in Vanda Pharmaceuticals has recently decreased by 0.63%, indicating that investor sentiment is improving.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

News Coverage This Week

MarketBeat has tracked 1 news article for Vanda Pharmaceuticals this week, compared to 4 articles on an average week.

Search Interest

4 people have searched for VNDA on MarketBeat in the last 30 days. This is an increase of 300% compared to the previous 30 days.

MarketBeat Follows

Only 1 people have added Vanda Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days.

Company Ownership

• Score: 3.3 / 5
• Insider Trading: Acquiring Shares

Insider Buying vs. Insider Selling

In the past three months, Vanda Pharmaceuticals insiders have bought 299.63% more of their company's stock than they have sold. Specifically, they have bought $128,400.00 in company stock and sold $32,130.00 in company stock.

Percentage Held by Insiders

Only 8.90% of the stock of Vanda Pharmaceuticals is held by insiders.

Percentage Held by Institutions

88.14% of the stock of Vanda Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

VNDA Stock Analysis - Frequently Asked Questions

How have VNDA shares performed this year?

Vanda Pharmaceuticals' stock was trading at $4.79 on January 1st, 2025. Since then, VNDA shares have increased by 4.3% and is now trading at $4.9940.

How were Vanda Pharmaceuticals' earnings last quarter?

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) issued its earnings results on Wednesday, May, 7th. The biopharmaceutical company reported ($0.50) earnings per share for the quarter, beating analysts' consensus estimates of ($0.55) by $0.05. The biopharmaceutical company earned $50.04 million during the quarter, compared to the consensus estimate of $45.13 million. Vanda Pharmaceuticals had a negative net margin of 21.98% and a negative trailing twelve-month return on equity of 8.30%.
Read the conference call transcript.

How do I buy shares of Vanda Pharmaceuticals?

Shares of VNDA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Vanda Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Vanda Pharmaceuticals investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Advanced Micro Devices (AMD), GE Aerospace (GE), Adobe (ADBE) and ServiceNow (NOW).

Company Calendar

• Last Earnings: 5/07/2025
• Today: 7/06/2025
• Next Earnings (Estimated): 7/30/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:VNDA
• CIK: 1347178
• Web: www.vandapharma.com
• Phone: (202) 734-3400
• Fax: 202-296-1450
• Employees: 290
• Year Founded: 2002

Price Target and Rating

• Average Stock Price Target: $16.50
• High Stock Price Target: $20.00
• Low Stock Price Target: $13.00
• Potential Upside/Downside: +230.4%
• Consensus Rating: Strong Buy
• Rating Score (0-4): 3.50
• Research Coverage: 2 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.75)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$18.90 million
• Net Margins: -21.98%
• Pretax Margin: -27.63%
• Return on Equity: -8.30%
• Return on Assets: -6.85%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 3.93
• Quick Ratio: 3.91

Sales & Book Value

• Annual Sales: $198.77 million
• Price / Sales: 1.48
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $9.24 per share
• Price / Book: 0.54

Miscellaneous

• Outstanding Shares: 58,930,000
• Free Float: 53,041,000
• Market Cap: $294.30 million
• Optionable: Optionable
• Beta: 0.68